About Alector, Inc. Common Stock
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Market Cap
$0.13B
Employees
238
Listed Since
February 7, 2019
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Website
www.alector.comPhone
415-231-5660
Headquarters
131 OYSTER POINT BLVD., SUITE 600
SOUTH SAN FRANCISCO, CA 94080
CIK
0001653087